Get started
TAHO PHARMACEUTICALS LTDTT

TAHO PHARMACEUTICALS LTD

67.2TWDR
−1.3−1.90%
At close at Jul 25, 07:00 GMT
TWD
No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

6467 fundamentals

Key facts

Market capitalization‪3.45 B‬TWD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−3.69TWD
Founded—
Employees (FY)—
CEOHoward Lee
Websitetahopharma.com
About

Taho Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products. Its Technology Platform products are the Transepithelial Delivery System, Transdermal DDS, Transmucosal SSD, and Bio-Revie. The firm's Research & Development products include medicines for migraine, alzheimer's disease, hyperactivity disorder, and nausea caused by chemotherapy. The company was founded on July 7, 2010 and is headquartered in Taipei, Taiwan.

Ownership
‪‪51.39 M‬‬
Closely held shares
‪‪36.05 M‬‬ (70.14%)
Free Float shares
‪‪15.34 M‬‬ (29.86%)
Closely held shares
‪‪36.05 M‬‬ (70.14%)
Free Float shares
‪‪15.34 M‬‬ (29.86%)
Capital structure
Market cap
‪‪3.45 B‬‬
Debt
‪‪16.65 M‬‬
Cash & equivalents
‪‪495.87 M‬‬
Enterprise value
‪‪2.97 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪3.45 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
H2 '17
H1 '18
H1 '23
H1 '24
H2 '24
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,400.0%‬
‪−2,000.0%‬
‪−1,600.0%‬
‪−1,200.0%‬
‪−800.0%‬
H2 '17
H1 '18
H1 '23
H1 '24
H2 '24
‪‪−105.00 M‬‬
‪‪−70.00 M‬‬
‪‪−35.00 M‬‬
‪0.00‬
‪‪35.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−100.00 M‬‬
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−100.00 M‬‬
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬

Dividends

Dividend yield, history and sustainability

No dividends
6467 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '17
H1 '18
H1 '23
H1 '24
H2 '24
‪‪−120.00 M‬‬
‪0.00‬
‪‪120.00 M‬‬
‪‪240.00 M‬‬
‪‪360.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪130.00 M‬‬
‪‪260.00 M‬‬
‪‪390.00 M‬‬
‪‪520.00 M‬‬
Assets
Liabilities